Laurion Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Laurion Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-13,272	Closed	-$158K	–	1349
2019 Q2	$158K	Buy	+13,272	New	+$160K	﹤0.01%	835
2018 Q3	–	Sell	-20,698	Closed	-$329K	–	1625
2018 Q2	$329K	Buy	+20,698	New	+$309K	﹤0.01%	1066

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Laurion Capital Management's VIVO Position: Q3 2019 in Review

Laurion Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q3 2019, closing a stake of 13,272 shares — an estimated $158K sold.

Laurion Capital Management first reported a position in VIVO in Q2 2018 and held it in 2 quarters. The position peaked at $329K in Q2 2018. 163 funds tracked by Wall St. Rank hold VIVO as of Q3 2019.

Laurion Capital Management reported no remaining Meridian Bioscience Inc position as of Q3 2019 after selling out during the quarter.
Laurion Capital Management sold 13,272 Meridian Bioscience Inc shares in Q3 2019, an estimated $158K.
Laurion Capital Management first reported a position in Meridian Bioscience Inc in Q2 2018 and held it in 2 quarters.
Laurion Capital Management's Meridian Bioscience Inc position peaked at $329K in Q2 2018.
163 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2019.

Based on Laurion Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.